Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF)

Blood (2024) 144 (Supplement 1): 1043.

https://doi.org/10.1182/blood-2024-206169

Published: 2024

Journal Articles

Prior Immune Effector Cell Therapy, Is Not Associated with an Increased Infectious Risk of Subsequent Bispecific Antibody Therapy for Multiple Myeloma

Lawrence Liu, Scott R. Goldsmith, Sheryl Leahey, Carlos Gomez Luna, Shawn Streeter, Adam Braun, Nitya Nathwani, Michael Rosenzweig, Firoozeh Sahebi, Azra Borogovac, Jonathan Keats, Myo Htut, Arnab Chowdhury, Sanjeet Singh Dadwal, Amrita Krishnan, Murali Janakiram

Blood (2023) 142 (Supplement 1): 1987.

https://doi.org/10.1182/blood-2023-188077

Published: 2023

Journal Articles

Total Marrow and Lymphoid Irradiation (TMLI) -Based Conditioning Regimen in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplant with Measurable Residual Disease

Blood (2023) 142 (Supplement 1): 2162.

https://doi.org/10.1182/blood-2023-185034

Published: 2023

Journal Articles

A Pilot Study of Reduced Intensity HLA-Haploidentical Hematopoietic Cell Transplantation (HaploHCT) with Post-Transplant Cyclophosphamide in Patients with Advanced Myelofibrosis

Haris Ali, Dongyun Yang, Sally Mokhtari, Ahmed Aribi, Joshua Mansour, Firoozeh Sahebi, Geoffrey P. Shouse, Idoroenyi Amanam, Salman Otoukesh, Anthony Stein, Stephen J. Forman, Guido Marcucci, Ryotaro Nakamura, Monzr M. Al Malki

Blood (2023) 142 (Supplement 1): 3566.

https://doi.org/10.1182/blood-2023-190449

Published: 2023

Journal Articles

Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations

Blood (2022) 140 (Supplement 1): 1890–1892.

https://doi.org/10.1182/blood-2022-169964

Published: 2022

Journal Articles

Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis

Blood (2022) 140 (Supplement 1): 1872–1874.

https://doi.org/10.1182/blood-2022-170323

Published: 2022

Journal Articles

Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-136384

Published: 2020

Journal Articles

Post-Transplant Cyclophosphamide for Graft Vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison By Donor Type; A Study from the Chronic Malignancies Working Party of the EBMT

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-137789

Published: 2020

Journal Articles

First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary Results

Blood (2019) 134 (Supplement_1): 4394.

https://doi.org/10.1182/blood-2019-126080

Published: 2019

Journal Articles

Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: Final Analysis of a Phase 1 Study

Michael Rosenzweig, Joycelynne Palmer, Ni-Chun Tsai, Ralf Buettner, PhD, Lupe Duarte, Myo Htut, Chatchada Karanes, Nitya Nathwani, MD, Flavia Pichiorri, PhD, Firoozeh Sahebi, Tim Synold, Xiwei Wu, James F Sanchez, Amrita Krishnan, MD, Stephen J Forman, Steven T Rosen

Blood (2018) 132 (Supplement 1): 2007.

https://doi.org/10.1182/blood-2018-99-120042

Published: 2018

Journal Articles

Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: A Phase 1 Trial

Michael Rosenzweig, MD, Joycelynne M. Palmer, PhD, Ni-Chun Tsai, MS, Ralf Buettner, PhD, Lupe Duarte, Myo Htut, Chatchada Karanes, Nitya Nathwani, Flavia Pichiorri, PhD, Firoozeh Sahebi, George Somlo, Tim Synold, PhD, Xiwei Wu, PhD, Amrita Krishnan, MD, Stephen J. Forman, MD FACP, Steven T. Rosen, MD

Blood (2017) 130 (Supplement 1): 3144.

https://doi.org/10.1182/blood.V130.Suppl_1.3144.3144

Published: 2017

Journal Articles

A Phase I/II Trial of Ixazomib (Ix), Pomalidomide (POM), and Dexamethasone (DEX), in Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients: Responses in Double/Triple Refractory Myeloma and Poor Risk Cytogenetics

Amrita Krishnan, Prashant Kapoor, MD, Joycelynne Palmer, PhD, Ni-Chun Tsai, MS, Shaji Kumar, MD, Sagar Lonial, MD FACP, Myo Htut, MD, Chatchada Karanes, MD, Nitya Nathwani, MD, Michael Rosenzweig, MD, Firoozeh Sahebi, MD, George Somlo, MD FACP, Lupe Duarte, CTA, Stephen J. Forman, MD, James F Sanchez, PhD, Jesus G. Berdeja, MD

Blood (2016) 128 (22): 3316.

https://doi.org/10.1182/blood.V128.22.3316.3316

Published: 2016

Journal Articles

Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT

Robert Chen, Joycelynne Palmer, PhD, Peter Martin, MD, Saro Armenian, DO, MPH, Nichun Tsai, Michelle Mott, Firoozeh Sahebi, Ji-Lian Cai, MD PhD, Tanya Siddiqi, MD, Leslie L. Popplewell, MD, John P. Leonard, MD, Auayporn P. Nademanee, MD, Steven T. Rosen, MD, Larry W. Kwak, MD, Stephen J. Forman, MD

Blood (2015) 126 (23): 519.

https://doi.org/10.1182/blood.V126.23.519.519

Published: 2015

Journal Articles

Results of a Phase II Trial of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT

Robert W Chen, MD, Joycelynne Palmer, PhD, Peter Martin, MD, Nicole Tsai, Young Kim, MD, Michelle Mott, RN, Firoozeh Sahebi, Tanya Siddiqi, MD, Leslie L. Popplewell, MD, John P. Leonard, MD, Tsiporah B. Shore, Stephen J. Forman

Blood (2014) 124 (21): 501.

https://doi.org/10.1182/blood.V124.21.501.501

Published: 2014

Journal Articles

NK Cell Recovery and Costimulatory Molecule Profiles after Autologous Hematopoietic Cell Transplantation (AHCT) in Multiple Myeloma (MM) Patients

Myo Htut, MD, Ghislaine Gallez-Hawkins, Joycelynne Palmer, PhD, Laetitia Jeannet, Leanne Goldstein, Andy Dagis, Ricardo Spielberger, MD, Pablo Miguel Parker, Len Farol, MD, Firoozeh Sahebi, MD, Chatchada Karanes, MD, Stephen J. Forman, Amrita Krishnan, MD, John A. Zaia, MD

Blood (2014) 124 (21): 2039.

https://doi.org/10.1182/blood.V124.21.2039.2039

Published: 2014

Journal Articles

Reduced Intensity Allogeneic Stem Cell Transplant In Patients With Multiple Myeloma: A Comparison Of Planned Autologous-Reduced Intensity Allogeneic Stem Cell Transplant (Auto-Allo) and Reduced Intensity Allogeneic Stem Cell Transplant (RIC) As Upfront Transplant In Patients With Multiple Myeloma, An EBMT Analysis

Firoozeh Sahebi, MD, Simona Iacobelli, Ph. D., Anja Van Biezen, Liisa Volin, MD, Peter Dreger, Mauricette Michallet, MD, PhD, Per T. Ljungman, MD, PhD, Goesta Gahrton, MD, PhD, Curly TCM Morris, MD, Stefan Schonland, Theo de Witte, MD, Laurent Garderet, MD, Nicolaus Kroeger, MD, Anja Henseler, Nicolaas PM Schaap, MD, PhD, D Caballero, Xavier Poire, MD, Jakob Passweg, Rose-Marie Hamljadi

Blood (2013) 122 (21): 920.

https://doi.org/10.1182/blood.V122.21.920.920

Published: 2013

Journal Articles

Phase I-II Trial of Tandem Autologous Transplantation with Melphalan Followed by Total Marrow Irradiation Ablative Therapy in Patients with Responding or Stable Mutiple Myeloma.

George Somlo, MD, Paul Frankel, PhD, Ricardo Spielberger, MD, Chatchada Karanes, MD, Amrita Krishnan, MD, Pablo Parker, MD, Leslie Popplewell, MD, Firoozeh Sahebi, MD, Timothy Schultheiss, PhD, Neil Martin Kogut, MD, David S. Snyder, MD, Anthony Selwyn Stein, M.D., Stephen J. Forman, MD, Jeffrey Wong, MD

Blood (2012) 120 (21): 3151.

https://doi.org/10.1182/blood.V120.21.3151.3151

Published: 2012

Journal Articles

Phase I Trial of Escalated Doses of Targeted Marrow Radiation Delivered by Tomotherapy Combined with Etoposide and Cyclophosphamide; An Allogeneic HCT Preparative Regimen for Patients with Advanced Leukemia

Anthony Selwyn Stein, MD, Jeffrey Wong, MD, Joycelynne Palmer, PhD, Margaret O'Donnell, MD, David S. Snyder, MD, Ni-Chun Tsai, MS MPH, Pablo Parker, MD, Len Farol, MD, Ricardo Spielberger, MD, Firoozeh Sahebi, MD, Neil Kogut, MD, Joyce Murata-Collins, PhD, David Senitzer, PhD, Stephen J. Forman, MD

Blood (2012) 120 (21): 218.

https://doi.org/10.1182/blood.V120.21.218.218

Published: 2012

Journal Articles

Tandem Autologous Hematopoietic Stem Cell Transplants (AuHCT) with or without Maintenance Therapy (auto-auto) Versus Single AuHCT Followed by HLA Matched Sibling Non- Myeloablative Allogeneic HCT (auto-allo) for Patients with Standard Risk (SR) Multiple Myeloma (MM): Results From the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial

Blood (2010) 116 (21): 41.

https://doi.org/10.1182/blood.V116.21.41.41

Published: 2010

Journal Articles

A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables.

Blood (2010) 116 (21): 3450.

https://doi.org/10.1182/blood.V116.21.3450.3450

Published: 2010

NARROW

Final Analysis of Phase 2a Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome (MDS), or Myelofibrosis (MF)

Prior Immune Effector Cell Therapy, Is Not Associated with an Increased Infectious Risk of Subsequent Bispecific Antibody Therapy for Multiple Myeloma

Total Marrow and Lymphoid Irradiation (TMLI) -Based Conditioning Regimen in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplant with Measurable Residual Disease

A Pilot Study of Reduced Intensity HLA-Haploidentical Hematopoietic Cell Transplantation (HaploHCT) with Post-Transplant Cyclophosphamide in Patients with Advanced Myelofibrosis

Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations

Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis

Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma

Post-Transplant Cyclophosphamide for Graft Vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison By Donor Type; A Study from the Chronic Malignancies Working Party of the EBMT

First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary Results

Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: Final Analysis of a Phase 1 Study

Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: A Phase 1 Trial

A Phase I/II Trial of Ixazomib (Ix), Pomalidomide (POM), and Dexamethasone (DEX), in Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients: Responses in Double/Triple Refractory Myeloma and Poor Risk Cytogenetics

Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT

Results of a Phase II Trial of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT

NK Cell Recovery and Costimulatory Molecule Profiles after Autologous Hematopoietic Cell Transplantation (AHCT) in Multiple Myeloma (MM) Patients

Phase I-II Trial of Tandem Autologous Transplantation with Melphalan Followed by Total Marrow Irradiation Ablative Therapy in Patients with Responding or Stable Mutiple Myeloma.

Phase I Trial of Escalated Doses of Targeted Marrow Radiation Delivered by Tomotherapy Combined with Etoposide and Cyclophosphamide; An Allogeneic HCT Preparative Regimen for Patients with Advanced Leukemia

A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only